A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Inclusion Criteria: Healthy Volunteers: * Adult healthy volunteers, 18-70 years of age * Weight \>/=50.0 kg * Body Mass Index (BMI) 18.0-40.0 kg/m2 * Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge * Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge * Medical history without major recent or ongoing pathology Patients with hepatic impairment: * Adult patients, 18-70 years of age * Weight \>/=50.0 kg * Body Mass Index (BMI) 18.0-40.0 kg/m2 * Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge * Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge * Stable, mild, moderate, or severe liver disease of cryptogenic, post-hepatic, hepatitis B or alcoholic origin Exclusion Criteria: Healthy Volunteers: * Pregnant or lactating women and male partners of women who are pregnant or lactating * Uncontrolled treated/untreated hypertension (systolic blood pressure \>/=160 mmHg and /or diastolic blood pressure \>/=105 mmHg * Any history of clinically significant cardiovascular or cerebrovascular disease * Creatinine clearance \</=60 mL/min * Positive test results for drugs or alcohol * Donation or loss of blood over 450 ml within 60 days prior to screening Patients with hepatic impairment: * Pregnant or lactating women and male partners of women who are pregnant or lactating * Uncontrolled treated/untreated hypertension (systolic blood pressure \>/=160 mmHg and /or diastolic blood pressure \>/=105 mmHg * Any history of clinically significant cardiovascular or cerebrovascular disease * Severe ascites at screening or admission to the clinic * History of or current severe hepatic encephalopathy (grade 3 or higher) * Any evidence of progressive liver disease within the last 4 weeks * History of liver transplantation * Creatinine clearance \</=60 mL/min * Positive test results for drugs or alcohol * Donation or loss of blood over 450 ml within 60 days prior to screening